Prospectus Supplement Reveals Terms of New $25M Equity Line and $1M Insider Purchase
ONMD sits 19% above its 52-week low of $0.49 on light trading volume (0.4× avg).
Summary
A new $25 million equity line with Yorkville and a $1 million insider stock purchase provide critical funding as OneMedNet faces going concern uncertainty.
Key Events · Financing and Capital Events · ONMD
-
New $25M Equity Line with Yorkville
The 2026 SEPA allows OneMedNet to sell up to $25 million of common stock to Yorkville at 97% of market price over a 36-month term, subject to a 4.99% beneficial ownership limit and a 19.99% issuance cap.
-
$1M Related Party Stock Purchase
In July 2026, a related party investor purchased 1,449,275 shares at $0.69 per share, generating $1.0 million in gross proceeds.
-
Going Concern Warning
The Q2 2026 Form 10-Q reiterates substantial doubt about the company's ability to continue as a going concern, with cash of only $0.4 million as of June 30, 2026.
-
Prior SEPA Expired
The 2024 SEPA commitment period expired in June 2026, reducing the derivative liability to $0 and ending that funding source.
Analysis · ONMD · Industrial Applications And Services
The prospectus supplement incorporates the Q2 2026 Form 10-Q, which reveals the specific terms of the new $25 million Standby Equity Purchase Agreement with Yorkville (2026 SEPA) and a $1 million related party subscription. The 2026 SEPA allows OneMedNet to sell shares at 97% of market price over 36 months, providing a crucial funding lifeline given the company's going concern warning and cash balance of only $0.4 million. The related party purchase by a director at $0.69 per share demonstrates insider confidence but also highlights the company's reliance on related party financing. The filing also confirms the expiration of the prior 2024 SEPA and the complete liquidation of Bitcoin holdings.
At the time of this filing, ONMD was trading at $0.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $34.6M. The 52-week trading range was $0.49 to $4.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.